Dianthus Therapeutics News

Dianthus Therapeutics (DNTH) Gets a Buy From Wedbush

TipRanksMay 10 08:46 ET

Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating

Dianthus Therapeutics (DNTH) has an average rating of buy and price targets ranging from $33 to $84, according to analysts polled by Capital IQ.

MT NewswiresMay 10 08:19 ET

Express News | Dianthus Therapeutics Inc : Jefferies Cuts Target Price to $38 From $39

ReutersMay 10 02:35 ET

Express News | Dianthus Therapeutics Inc: Qtrly Shr Loss $0.54

ReutersMay 9 16:58 ET

Express News | Dianthus Therapeutics: Cash, Cash Equivalents and Short-Term Investments as of March 31, Projected to Provide Runway Into 2H 2027

ReutersMay 9 16:58 ET

Dianthus Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 16:53 ET · Announcements

Express News | Dianthus Therapeutics Q1 EPS $(0.54) Misses $(0.44) Estimate, Sales $874.00K Beat $460.00K Estimate

BenzingaMay 9 16:46 ET

Dianthus Therapeutics 1Q Loss/Shr 54c >DNTH

Dianthus Therapeutics 1Q Loss/Shr 54c >DNTH

Dow JonesMay 9 16:06 ET

Express News | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

ReutersMay 9 16:01 ET

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

Yahoo FinanceMay 8 16:30 ET

Express News | Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersMay 3 16:30 ET

Disappointing Week for Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Institutional Investors Who Control 28% of the Company

Key Insights Institutions' substantial holdings in Dianthus Therapeutics implies that they have significant influence over the company's share price 56% of the business is held by the top 6 sharehol

Simply Wall StApr 22 08:13 ET

Dianthus Therapeutics Is Maintained at Outperform by Raymond James

Dianthus Therapeutics Is Maintained at Outperform by Raymond James

Dow JonesApr 18 13:15 ET

Dianthus Therapeutics Price Target Raised to $51.00/Share From $34.00 by Raymond James

Dianthus Therapeutics Price Target Raised to $51.00/Share From $34.00 by Raymond James

Dow JonesApr 18 13:15 ET

Express News | Dianthus Therapeutics Inc : Raymond James Raises Target Price to $51 From $34: Raymond James Raises Target Price to $51 From $34

Moomoo 24/7Apr 18 07:12 ET

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. ("Dianthus"), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement

GlobeNewswireApr 5 16:30 ET

The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation

Yahoo FinanceMar 27 08:19 ET

Dianthus Therapeutics' High-Stakes Gamble: Navigating Regulatory Risks and Supplier Challenges in Novel Drug Delivery

TipRanksMar 23 02:01 ET

Express News | Dianthus Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results. Also, Wedbush Maintained an Outperform Rating on the Stock and Raised Its Price Target From $24 to $33

Moomoo 24/7Mar 22 10:54 ET

Dianthus Therapeutics Is Maintained at Outperform by Wedbush

Dianthus Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesMar 22 10:11 ET